{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"64"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"7"},{"groupId":"OG006","value":"6"}],"units":"Participants"}],"description":"Number of participants with NAb positive against PF-06801591 after IV and SC dosing - Part 1 and Part 2. A participant was NAb positive if (1) baseline titer was missing or negative and participant had ≥ 1 post-treatment positive titer (treatment-induced), or (2) positive titer at baseline and had a ≥ 0.602 in titer from baseline in ≥ 1 post-treatment sample (treatment-boosted). Participants who were NAb positive at baseline but did not become boosted post-treatment were considered as NAb negative.","groups":[{"description":"Participants received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 419 days)","id":"OG000","title":"Part 1: PF-06801591 300 mg (Subcutaneously [SC])"},{"description":"Participants with NSCLC received PF-06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 851 days)","id":"OG001","title":"Part 2: PF-06801591 300 mg (SC) for NSCLC"},{"description":"Participants with UC received PF- 06801591 300 mg SC every 4 weeks for 28-day cycles. (maximum of 841 days)","id":"OG002","title":"Part 2: PF-06801591 300 mg (SC) for UC"},{"description":"Participants received PF-06801591 0.5 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1186 days)","id":"OG003","title":"Part 1: PF-06801591 0.5 mg/kg (Intravenously [IV])"},{"description":"Participants received PF-06801591 1 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 659 days)","id":"OG004","title":"Part 1: PF-06801591 1 mg/kg (IV)"},{"description":"Participants received PF-06801591 3 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 1606 days)","id":"OG005","title":"Part 1: PF-06801591 3 mg/kg (IV)"},{"description":"Participants received PF-06801591 10 mg/kg IV every 3 weeks for 21-day cycles. (maximum of 445 days)","id":"OG006","title":"Part 1: PF-06801591 10 mg/kg (IV)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population included all participants who received at least 1 dose of study treatment and had at least 1 post-treatment ADA result. NAb-negative participants included participants who were ADA negative or ADA-positive participants who tested negative in the NAb assay.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of treatment (maximum of 851 days)","title":"Number of Participants With Neutralizing Antibodies (NAb) Positive Against PF-06801591 - Part 1 and Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}